Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477376 | 0.88 | MAPT (0.50) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29719317 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496385 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29719344 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496248 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496253 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496246 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496355 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18496256 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29719385 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| CN-109311882-B | Adenine derivatives as protein kinase inhibitors | BCI制药公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| EP-3452477-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. Pharma (BE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191297-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | BCI PHARMA (FR) | 2017-11-09 | — | — | WO | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20110070297-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1948614-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007061923-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | MAPT 3122/4885ALDH1A1 3196/4885CYP1A2 3450/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | MAPT 3122/4885ALDH1A1 3196/4885CYP1A2 3450/4885 |
| US-20070197532-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | MAPT 3294/4885ALDH1A1 1527/4885CYP1A2 2010/4885 |
| US-20110070297-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | MAPT 3294/4885ALDH1A1 1527/4885CYP1A2 2010/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | MAPT 2603/4885ALDH1A1 3631/4885CYP1A2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.